Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PACAP27 induces migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Episodic and Chronic Cluster Headache: Differences in Family History, Traumatic Head Injury, and Chronorisk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Medication-overuse headache: The effect of a patient educational programme-A randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. More precise phenotyping of cluster headache using prospective attack reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Medication-overuse headache leads to high disability and decreased quality of life, and the best approach for withdrawal has been debated.

AIM: To compare change in disability and quality of life between two withdrawal programs.

METHODS: We randomized medication-overuse headache patients to program A (two months without acute analgesics or migraine medications) or program B (two months with acute medications restricted to two days/week) in a prospective, outpatient study. At 6 and 12 months, we measured disability and headache burden by the Headache Under-Response to Treatment index (HURT). We estimated quality of life by EUROHIS-QOL 8-item at 2-, 6-, and 12-month follow-up. Primary endpoint was disability change at 12 months.

RESULTS: We included 72 medication-overuse headache patients with primary migraine and/or tension-type headache. Fifty nine completed withdrawal and 54 completed 12-month follow-up. At 12-month follow-up, 41 patients completed HURT and 38 completed EUROHIS-QOL 8-item. Disability reduction was 25% in program-A and 7% in program-B ( p = 0.027). Headache-burden reduction was 33% in program-A and 3% in program-B ( p = 0.005). Quality of life was increased by 8% in both programs without significant difference between the programs ( p = 0.30). At 2-month follow-up, quality of life increased significantly more in program-A than program-B ( p = 0.006).

CONCLUSION: Both withdrawal programs reduced disability and increased quality of life. Withdrawal without acute medication was the most effective in reducing disability in medication-overuse headache patients.

TRIAL REGISTRATION: Clinicaltrials.gov (NCT02903329).

OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind39
Udgave nummer7
Sider (fra-til)863-872
ISSN0333-1024
DOI
StatusUdgivet - 2019

ID: 56703816